Cerus Corp. Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Socie...
December 04 2020 - 7:00PM
Business Wire
Cerus Corporation (Nasdaq: CERS) today announced the oral
presentation of a clinical study: “Efficacy of COVID-19 Pathogen
Inactivated Convalescent Plasma for Patients with Moderate to
Severe Acute COVID-19: A Case Matched Control Study,” presented by
Dr. Nina Khanna of the University Hospital of Basel, Switzerland,
at the American Society of Hematology Annual Meeting, on Saturday,
December 5, 2020, at 2:45 pm/EST. This presentation reviews data on
the efficacy of INTERCEPT-treated COVID-19 convalescent plasma
(CCP) to treat COVID-19 pneumonia patients.
Initiated in March 2020, the study was conducted in
collaboration with Cerus and Vitalant Research Institute, San
Francisco; Vaccine Research and Development Laboratory, University
of California, Irvine, CA; and Enable Biosciences, San Francisco,
CA.
The study of hospitalized patients with documented COVID-19
pneumonia enrolled 15 subjects who received INTERCEPT-treated CCP
and 30 matched controls who received standard therapy without CCP
transfusion. Of the 15 patients treated with INTERCEPT-treated CCP,
14 (93.3%) responded and were alive at study day 28. Three patients
were severely immune-compromised. Among the 30 matched control
patients, 6 (20%) died by study day 28.
“The study summarizes the successful collaboration with the
University Hospital of Basel, Cerus, and the other California-based
research teams, generating important data to define CCP
virus-neutralizing efficacy at the onset of the COVID-19 pandemic.
We are encouraged by the patients’ responses to INTERCEPT-treated
CCP and the preservation of neutralizing antibodies in
INTERCEPT-treated CCP. The data from this study demonstrate the
ability to identify effective CCP during epidemics that, with
pathogen reduction to decrease the risk of transfusion-transmitted
disease, can be rapidly introduced into routine practice,” said Dr.
Laurence Corash, Cerus’ chief scientific officer.
To view the oral presentation on Saturday, December 5, click
here:
https://ash.confex.com/ash/2020/webprogram/Paper136180.html
About University Hospital of Basel and the Regional Swiss Red
Cross Blood Transfusion Center, Basel, Switzerland.
The University Hospital of Basel is a specialized medical
research and patient care facility. The Regional Swiss Red Cross
Blood Transfusion Center, located in the University Hospital,
conducts research studies in transfusion medicine.
About Cerus
Cerus Corporation is dedicated solely to safeguarding the
world’s blood supply and aims to become the preeminent global blood
products company. Headquartered in Concord, California, the company
develops and supplies vital technologies and pathogen-protected
blood components to blood centers, hospitals, and ultimately
patients who rely on safe blood. The INTERCEPT Blood System for
platelets and plasma is available globally and remains the only
pathogen reduction system with both CE mark and FDA approval for
these two blood components. The INTERCEPT red blood cell system is
under regulatory review in Europe, and in late-stage clinical
development in the US. Also in the US, the INTERCEPT Blood System
for Cryoprecipitation is approved for production of Pathogen
Reduced Cryoprecipitated Fibrinogen Complex, a therapeutic product
for the treatment and control of bleeding associated with
fibrinogen deficiency, including massive hemorrhage. For more
information about Cerus, visit www.cerus.com and follow us on
LinkedIn.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201204005617/en/
Jessica Hanover – VP, Corporate Affairs Cerus Corporation
925-288-6137
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Apr 2023 to Apr 2024